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A B S T R A C T
Background: The use of statins prior to percutaneous coronary intervention (PCI) has reduced cardiac 
events in both short and long-term follow-up. This study assessed the impact of prior statin use on in-
hospital PCI outcomes in patients with acute coronary syndrome (ACS). 
Methods: Retrospective analysis of a multicenter registry of 6,288 consecutive patients undergoing PCI. Of 
these, 35% had ACS and were evaluated according to statin use (Group 1, n = 1,203) or no use (Group 2, n = 999). 
Results: Group 1 showed higher prevalence of dyslipidemia, acute myocardial infarction (AMI), previous 
coronary artery bypass graft, chronic renal failure, multivessel involvement, bifurcation lesions, and use 
of drug-eluting stents. Group 2 showed more primary and rescue PCIs, Killip functional class III/IV, B2/C 
lesions, thrombi, total occlusions, pre-procedural TIMI 0/1 flow, presence of collateral circulation, and use 
of glycoprotein IIb/IIIa inhibitors and aspiration catheters. PCI success was higher in Group 1 (95.1% vs. 
92.5%; p = 0.01), and the occurrence of major adverse cerebrovascular and cardiac events (MACCE) (3.7% vs. 
5.7%) was more frequent in Group 2. Although the non-use of statins showed an association with MACCE 
in the univariate analysis, independent predictors of in-hospital MACCE were limited to AMI in Killip III/IV 
and prior coronary artery bypass graft.
Conclusions: ACS patients undergoing PCI who previously used statins had better in-hospital clinical 
outcomes; however, statin use was not an independent predictor of MACCE.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Impacto do uso prévio de estatinas nos resultados da intervenção coronária 
percutânea na síndrome coronariana aguda
R E S U M O
Introdução: O uso de estatinas previamente à intervenção coronária percutânea (ICP) tem reduzido 
eventos cardíacos na evolução de curto e longo prazos. Avaliamos o impacto do uso prévio de estatinas nos 
resultados hospitalares da ICP em pacientes com síndrome coronariana aguda (SCA). 
Métodos: Análise retrospectiva de registro multicêntrico com 6.288 pacientes submetidos consecutivamente 
à ICP. Destes, 35% tinham SCA e foram avaliados de acordo com a utilização (Grupo 1, n = 1.203) ou não (Grupo 
2, n = 999) de estatinas. 
Resultados: O Grupo 1 mostrou maior prevalência de dislipidemia, infarto agudo do miocárdio (IAM) prévio, 
procedimentos de revascularização prévios, insuficiência renal crônica, acometimento multiarterial, 
lesões em bifurcação uso de stents farmacológicos. O Grupo 2 mostrou maior número de ICPs primária e de 
resgate, classe funcional Killip III/IV, lesões tipo B2/C, trombos, oclusões totais, fluxo TIMI pré 0/1, presença 
de circulação colateral, uso de inibidores da glicoproteína IIb/IIIa e de cateteres de aspiração. O sucesso da 
ICP foi maior no Grupo 1 (95,1% vs. 92,5%; p = 0,01), e a ocorrência de eventos cardíacos e cerebrovasculares 
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Introduction
With the current technological advances, percutaneous coro-
nary intervention (PCI) has become the most commonly used the-
rapeutic approach in the treatment of coronary artery disease 
(CAD). Although it restores myocardial flow, PCI carries a potential 
risk of myocardial damage, which is associated with increased 
morbidity and mortality due to late cardiac events.1-3 Many thera-
peutic strategies have been proposed to limit the occurrence and 
extent of periprocedural myocardial damage; however, myocardial 
injury still remains the most common complication of PCI.4-6 The-
refore, understanding the mechanisms and finding adjunctive the-
rapies to improve myocardial protection remain a challenge in 
modern Cardiology.
It has been increasingly demonstrated that statins have pleiotropic 
actions with beneficial effect on the cardiovascular system, which go 
far beyond simply the control of cholesterol level. These effects inclu-
de improved endothelial function by increasing the levels and bioacti-
vity of nitric oxide, anti-inflammatory and antioxidant effects, and 
plaque stabilization.7,8
Based on these findings, it has been hypothesized that the use of 
statins may be associated with decreased rates of periprocedural acu-
te myocardial infarction (AMI) by reducing the release of myocardial 
necrosis markers during the PCI through their pleiotropic effects on 
microcirculation. Several randomized studies have demonstrated the 
reduction in periprocedural AMI with high-dose statin use before PCI, 
and some have documented a reduction in major adverse cardiac 
events.9-13 Coronary flow improvement and mortality reduction have 
also been reported in patients that were chronic statin users and were 
submitted to primary PCI.14-17 However, in Brazil, there are no regis-
tries with a large number of patients evaluating whether the previous 
use of statin has an impact on major adverse cerebrovascular and car-
diovascular events (MACCE) in patients with acute coronary syndro-
me (ACS) submitted to PCI.
In this retrospective observational study, the authors aimed to 
assess the impact of the prior use of statins on in-hospital outcomes 
of PCI in patients with ACS.
Methods
Population
From August 2006 to October 2012, 6,288 consecutive patients 
were submitted to PCI at the centers that comprise the Angiocardio 
Registry (Hospital Bandeirantes, Hospital Rede D'Or São Luiz Anália 
Franco, and Hospital Leforte in Sao Paulo; Hospital Vera Cruz in Cam-
pinas; and Hospital Regional do Vale do Paraíba in Taubaté – all in the 
State of São Paulo). Of these patients, 2,202 (35%) had a diagnosis of 
ACS and were assessed according to statin use (Group 1, n = 1,203) or 
no use (Group 2, n = 999).   
Data were collected prospectively and stored in a computerized 
database available online in all centers participating in the registry.
The primary objective was to compare in-hospital MACCE rates 
between the two groups and assess the independent predictors of 
these events.
Medication
Statin use prior to hospitalization for ACS, regardless of the type, 
dose, and time of administration was considered previous statin use. 
All patients, irrespective of previous treatment or lack thereof, recei-
ved simvastatin, rosuvastatin, or atorvastatin during hospitaliza-
tion, according to the protocols of the institutions that comprise the 
Angiocardio Registry.
Procedure
Most interventions were performed through femoral approach, 
whereas the radial approach was used in the others. The technique 
and the choice of material during the procedure were at the discre-
tion of the operators, as well as evaluating the need for the use of 
glycoprotein IIb/IIIa inhibitors. Unfractionated heparin was used at 
the beginning of the procedure at a dose of 70 U/kg to 100 U/kg, ex-
cept in patients who were already receiving low-molecular-weight 
heparin.
All patients received combined antiplatelet therapy with acetyl-
salicylic acid (ASA), at loading doses of 300 mg and maintenance do-
ses of 100 to 200 mg/day, and clopidogrel, at loading doses of 300 or 
600 mg and maintenance doses of 75 mg/day. The femoral sheaths 
were removed 4 hours after the start of heparinization. Radial sheaths 
were removed immediately after the procedure. 
The measurements of myocardial necrosis marker creatine kinase-
-MB (CK-MB) activity considered for the analysis were performed im-
mediately before the procedure and 12 hours afterwards. 
Angiographic analysis and definitions
Angiographic analyses were performed in at least two orthogonal 
projections by experienced operators, using digital quantitative an-
giography. This study used the same angiographic criteria found in 
the database of the National Center of Cardiovascular Interventions 
(Central Nacional de Intervenções Cardiovasculares [CENIC]) of the 
Brazilian Society of Interventional Cardiology (Sociedade Brasileira de 
Hemodinâmica e Cardiologia Intervencionista [SBHCI]). The lesion 
type was classified according to the criteria of the American College of 
Cardiology and the American Heart Association (ACC/AHA).18 The 
Thrombolysis in Myocardial Infarction (TIMI) classification was used 
to determine pre- and post-procedure coronary flow.19 Procedural 
success was defined as attaining angiographic success (residual ste-
nosis < 30% with TIMI 3 flow) and no MACCE, including death from 
any cause, periprocedural reinfarction, stroke, and emergency coro-
nary artery bypass graft surgery.20 
Periprocedural reinfarction was defined as the appearence of typi-
cal pain with electrocardiographic alterations (ST-segment elevation 
or pathological Q waves) and/or angiographic evidence of target-ves-
sel occlusion. The results of post-PCI CK-MB were not included in this 
adversos maiores (ECCAM) (3,7% vs. 5,7%; p = 0,04) foi mais frequente no Grupo 2. Apesar da não utilização 
de estatina ter apresentado associação com ECCAM na análise univariada, foram preditores independentes 
de ECCAM hospitalares apenas o IAM em Killip III/IV e a cirurgia de revascularização prévia. 
Conclusões: Pacientes com SCA submetidos à ICP e que estavam em uso prévio de estatinas apresentaram 
melhores resultados clínicos hospitalares, mas a utilização desses fármacos não foi preditora independente 
de ECCAM. 
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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definition. Emergency coronary artery bypass graft surgery was de-
fined as a procedure performed immediately after the PCI.
Statistical analysis 
The data stored in an Oracle-based database were plotted on Excel 
spreadsheets and analyzed using Statistical Package for the Social 
Science version 15.0 (SPSS Inc., Chicago, USA). Continuous variables 
were expressed as mean ± standard deviation, and categorical variables 
as absolute number and percentage. The associations between conti-
nuous variables were assessed by Student’s t-test, and nonparametric 
tests (Mann-Whitney and Wilcoxon) were used for non-normal distri-
bution (pre- and post-PCI CK-MB). Associations between categorical 
variables were evaluated by the Chi-squared test, Fisher's exact test, or 
the likelihood ratio test, as appropriate. Significance level was set at p < 
0.05. Simple and multiple logistic regression models were applied to 
identify MACCE predictors.
Results
Clinical characteristics are shown in Table 1. Group 1 showed hi-
gher prevalence of dyslipidemia, previous AMI, previous coronary 
artery bypass graft, previous PCI, and chronic renal failure. Group 2 
demonstrated a higher number of patients with ST-segment eleva-
tion myocardial infarction (STEMI) and more advanced functional 
class (Killip III and IV).
From the angiographic viewpoint (Table 2), patients who used 
statins had more multivessel involvement and bifurcation lesions. 
Group 2 patients had more type B2/C lesions, lesions with thrombi 
Table 1
Clinical characteristics.
Characteristics Group  1 
(n = 1,203)
Group  2 
(n = 999)
p-value
Age, years 61.1 ± 11.9 60.9 ± 13.2 0.72
Male gender, n (%) 804 (66.8) 679 (68.0) 0.60
Smoking, n (%) 390 (32.4) 288 (28.8) 0.08
Arterial hypertension, n (%) 869 (72.2) 695 (69.6) 0.18
Dyslipidemia, n (%) 409 (34.0) 236 (23.6) < 0.01
Diabetes, n (%) 342 (28.4) 249 (24.9) 0.07
Previous AMI, n (%) 178 (14.8) 102 (10.2) < 0.01
Previous coronary artery bypass graft, n (%) 114 (9.5) 64 (6.4) 0.01
Chronic renal failure, n (%) 44 (3.7) 20 (2.0) 0.03
Previous stroke, n (%) 41 (3.4) 25 (2.5) 0.26
Previous PCI, n (%) 228 (19.0) 154 (15.4) 0.03
Clinical presentation, n (%) < 0.01
Post-infarction angina 456 (37.9) 168 (16.8)
STEMI 220 (18.3) 560 (56.1)
NSTEMI 527 (43.8) 271 (27.1)
Killip, n (%) < 0.01
I 175 (79.6) 409 (73.0)
II 35 (15.9) 74 (13.2)
III 3 (1.4) 20 (3.6)
IV 7 (3.2) 57 (10.2)
AMI: acute myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; NSTEMI: non ST-segment elevation myocardial infarction.
Table 2
Angiographic characteristics.
Characteristic Group 1 
(n = 1,203/1,569 vessels/1,718 lesions)
Group 2 
(n = 999/1,249 vessels/1,378 lesions)
p-value
Coronary disease extension, n (%) 0.01
One-vessel 875 (72.7) 781 (78.2)
Two-vessel 269 (22.4) 172 (17.2)
Three-vessel 59 (4.8) 46 (4.6)
Treated vessels, n (%) 0.01
Right coronary artery 472 (30.1) 425 (34.0)
Left circumflex artery 374 (23.8) 238 (19.1)
Left anterior descending artery 661 (42.1) 545 (43.6)
Grafts 52 (3.3) 32 (2.6)
Left main coronary artery 10 (0.6) 9 (0.7)
B2/C lesions, n (%) 979 (63.2) 817 (69.2) < 0.01
Calcified lesions, n (%) 660 (38.5) 646 (46.9) < 0.01
Thrombotic lesions, n (%) 240 (14.0) 385 (28.0) < 0.01
Long lesions (> 20 mm), n (%) 222 (13.0) 156 (11.3) 0.19
Bifurcation lesions, n (%) 147 (8.6) 84 (6.1) 0.01
Total occlusions, n (%) 290 (16.9) 532 (38.6) < 0.01
Left ventricular dysfunction, n (%) 94 (49.7) 74 (60.7) 0.08
TIMI flow, pre n (%) < 0.01
0/1 325 (19.0) 596 (43.3)
2/3 1,389 (81.0) 781 (56.7)
Collateral circulation, n (%) 325 (18.9) 322 (23.4) < 0.01
TIMI: Thrombolysis in Myocardial Infarction.
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and calcified occlusions, higher prevalence of pre-PCI TIMI 0/1 flow, 
and the presence of collateral circulation.
As for the procedural characteristics (Table 3), Group 1 used more 
drug-eluting stents with a higher stent/patient ratio, whereas Group 
2 had more coronary interventions in the acute phase of myocardial 
infarction (primary or rescue), and higher use of glycoprotein IIb/IIIa 
inhibitors and thrombus aspiration catheters. The post-procedural 
CK-MB activity values were higher than the pre-PCI values in both 
groups, although Group 1 had lower values than Group 2. Procedural 
success was higher in Group 1 (95.1% vs. 92.5%; p = 0.01)
Table 4 indicates the clinical outcomes during the in-hospital 
phase. The occurrence of MACCE (3.7% vs. 5.7%; p = 0.04) and death 
(1.4% vs. 3.2%; p < 0.01) was more frequent in Group 2.
At the univariate analysis, the variables age, calcified lesions, 
long lesions, thrombotic lesions, previous coronary artery bypass 
graft, presence of collateral circulation, primary PCI, use of glyco-
protein IIb/IIIa inhibitors, pre-PCI TIMI 0/1 flow, Killip III and IV, and 
no use of statins showed a significant association with the occurren-
ce of MACCE. At the multivariate analysis (Table 5), only the presen-
ce of AMI in Killip III/IV (odds ratio - OR 6.33; 95% confidence interval 
- 95% CI 3.45 - 11.45; p < 0.01) and previous coronary artery bypass 
graft (OR 4.06; 95% CI 1.47 - 10.05; p < 0.01) were the variables that 
best explained the occurrence of hospital MACCE.
Discussion
The importance of statins in primary and secondary cardiovascular 
prevention comes from their lipid-lowering effects, with significant re-
duction in low-density lipoprotein-cholesterol (LDL-C), as well as their 
pleiotropic effects, with improvement in endothelial function and anti-
-inflammatory and antioxidant actions, leading to atherosclerotic pla-
que stabilization – the latter shown as reduced atherosclerotic plaque 
volume by intravascular ultrasound in the REVERSAL study.7,8,21 Re-
cently, Komukai et al. demonstrated, through optical coherence tomo-
graphy, the increased atherosclerotic plaque fibrous cap thickness and 
lipid arc as well as macrophage reduction after treatment with atorvas-
tatin (more significant with a 20 mg dose), contributing to the patho-
physiological understanding of this process.22
However, in spite of the present study’s evidence, nearly half of the 
patients (45.3%) had no previous statin therapy, despite the presence 
of dyslipidemia and diabetes in almost 25%, disclosing a probable pri-
mary cardiovascular prevention failure in Brazil. The higher number 
of patients with AMI in this group suggests the possible clinical im-
pact of the absence of the statin protective effect, as well as evidence 
that many patients start prevention (this time, secondary) only after 
having suffered a major event. Patients with previous statin use, des-
pite being more complex from a clinical point of view, due to the hi-
Table 3
Characteristics of procedures.
Characteristic Group 1 
(n = 1,203/1,569 vessels/1,718 lesions)
Group 2 
(n = 999/1,249 vessels/1,378 lesions)
p-value
Treated vessels/patient 1.3 ± 0.6 1.3 ± 0.6 < 0.01
Stent/patient ratio 1.3 ± 0.7 1.1 ± 0.7 < 0.01
Stent use, n (%) 1,419 (90.4) 1,068 (85.5) < 0.01
Drug-eluting stents 284 (20.0) 139 (13.0) < 0.01
Stent diameter, mm 3.00 ± 0.48 3.05 ± 0.51 < 0.01
Stent length, mm 19.1 ± 7.1 19.7 ± 6.9 0.06
Intervention types, n (%) < 0.01
Primary PCI 137 (11.4) 413 (41.3)
Rescue PCI 59 (4.9) 131 (13.1)
Glycoprotein IIb/IIIa inhibitors, n (%) 144 (12.0) 175 (17.5) < 0.01
Pre-PCI CK-MB, U/L 34.5 ± 84.4 66.9 ± 137.8 < 0.01
CK-MB 12 hours post-PCI, U/L 35.5 ± 92.5 85.2 ± 153.6 < 0.01
Thromboaspiration, n (%) 51 (4.5) 101 (11.4) < 0.01
TIMI flow, post, n (%) < 0.01
0/1 34 (2.1) 70 (5.3)
2/3 1,589 (97.9) 1,241 (94.7)
Degree of stenosis, %
Pre 85.76 ± 12.69 90.22 ± 12.83 < 0.01
Post 3.64 ± 15.74 7.21 ± 23.01 < 0.01
Procedural success, n (%) 1,144 (95.1) 924 (92.5) 0.01
PCI: percutaneous coronary intervention; TIMI: Thrombolysis in Myocardial Infarction.
Table 4
In-hospital clinical outcomes.
Characteristic Group 1 
(n = 1,203)
Group 2 
(n = 999)
p-value
MACCE, n (%) 45 (3.7) 57 (5.7) 0.04
In-hospital death, n (%) 17 (1.4) 32 (3.2) < 0.01
Emergency coronary artery bypass graft, n (%) 1 (0.1) 1 (0.1) > 0.99
Stroke, n (%) 2 (0.2) 2 (0.2) > 0.99
Acute myocardial reinfarction, n (%) 31 (2.6%) 27 (2.7%) 0.96
MACCE: major adverse cardiac and cerebrovascular events.
Table 5
Independent predictors of major adverse cardiac and cerebrovascular events.
Factors OR 95% CI p-value
Previous coronary artery bypass graft 4.06 1.47-0.05 < 0.01
Killip III-IV 6.33 3.45-11.45 < 0.01
OR: odds ratio; 95% CI: 95% confidence interval.
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gher frequency of prior AMI, coronary artery bypass graft, PCI, and 
chronic renal failure, demonstrating the prescription of statins as se-
condary prevention, showed a more favorable clinical profile, with 
ACS without ST-segment elevation predominating in this group, and 
lower occurrence of severe hemodynamic consequences (Killip III and 
IV) in those who presented with STEMI. 
Another important aspect is that although the group with prior 
use of statins had a higher incidence of multivessel disease, more 
complex lesions (lesions type B2 and C, calcified lesions, lesions with 
thrombus, total occlusions, and TIMI 0/1 flow) were significantly 
more frequent in the group not receiving statins. Due to the nature 
of the study, it cannot be inferred that these findings are directly 
related to a protective effect of statins, but it can be used as a hypo-
thesis generator.
Recent evidence has shown that high doses of statins increase 
their beneficial cardiovascular pleiotropic effects, which are indepen-
dent from the reducing effect on cholesterol levels, as the latter only 
occurs with long-term treatment.23,24 The ARMYDA (Atorvastatin for 
Reduction of Myocardial Damage during Angioplasty), ARMYDA-ACS 
(Atorvastatin for Reduction of Myocardial Damage during Angioplas-
ty-Acute Coronary Syndromes), ARMYDA-RECAPTURE (Atorvastatin 
for Reduction Myocardial Damage During Angioplasty), and NAPLES II 
(Novel Approaches for Preventing or Limiting Events II) studies, which 
evaluated the acute effects of atorvastatin on PCIs, showed that pre-
-treatment with atorvastatin significantly reduced the occurrence of 
periprocedural AMI.9,10,25,26 That finding, although often evidenced 
only by an increase in post-PCI myocardial necrosis markers, is rela-
ted to increased rates of major adverse cardiac events in the follow-
-up.27,28 The present study showed an increase in mean post-PCI 
CK-MB values in both groups; patients who have made previous use of 
statins showed lower pre- and post-PCI values than the other group, 
which may indicate a cardiovascular protective effect of medication. 
Higher baseline values in the group that did not use statins may also 
be a result of a higher number of patients with STEMI. 
The reduction of major adverse cardiovascular events after PCI 
with the use of statins has been well demonstrated in randomized 
studies in selected patients with no previous use of the assessed me-
dication.9,10,12,13,25 However, the ROMA II11 and ARMYDA-RECAPTU-
RE26 studies included patients that were chronic users of statins, 
who received additional high doses of atorvastatin or rosuvastatin 
on the day of the procedure. Interestingly, although these two stu-
dies demonstrate significant beneficial effects of the study drug on 
the reduction of major adverse cardiovascular events, they were not 
as evident as those reported in other publications. This fact would 
appear to demonstrate that prior use of statins could exert some 
protective effect on PCI results. Corroborating this hypothesis, stu-
dies of patients with STEMI have suggested that prior chronic use of 
statins may improve coronary flow and be associated with lower 
short-term mortality (30 days).14-17
In the present study with ACS patients, the procedure success 
rate was significantly higher in patients with previous statin use. 
The occurrence of TIMI 2/3 flow, which resulted in a lower incidence 
of clinical events in this group, reinforced the hypothesis that there 
may be cardiovascular protective effects of prior statin use regar-
ding in-hospital PCI outcomes. Although the non-chronic use of sta-
tins showed a significant association with the occurrence of MACCE 
in the univariate analysis in this study, only the presence of STEMI in 
Killip III/IV and prior coronary artery bypass graft were independent 
predictors of in-hospital MACCE.
Study limitations
The retrospective data analysis, the absence of late follow-up, the 
non-inclusion of changes in myocardial necrosis markers in the 
diagnosis of periprocedural reinfarction, the use of CK-MB activity 
to the detriment of CK-MB mass or troponin, and the lack of standar-
dization of statin dose, type, and time of use may be considered limi-
tations of this study.
Conclusions
Patients with acute coronary syndrome submitted to percutaneous 
coronary intervention who were prior statin users had better clinical 
outcomes. However, statin use was not an independent predictor of in-
-hospital major adverse cardiac and cerebrovascular events. 
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